Skip to main content

Table 4 Dynamic changes of variables between baseline and after 3 cycles of (R)-CHOP in DLBCL patients

From: Study on influencing factors of anthracycline-induced subclinical cardiotoxicity in DLBCL patients administered (R)-CHOP

Variable At baseline After 3 cycles of (R)-CHOP P-value d (after—baseline)a
HDL-C
 No-AISC 1.07 (0.81, 1.38) 1.27 (0.96, 1.49) 0.010 0.18 (-0.14, 0.27)
 AISC 0.97 (0.86, 1.20) 1.08 (0.81, 1.61) 0.219 0.09 (-0.16, 0.28)
P-value 0.410 0.062   0.005
ApoA1
 No-AISC 1.18 ± 0.36 1.34 ± 0.2 0.038 1.22 ± 0.33
 AISC 1.17 ± 0.29 1.24 ± 0.30 0.145 1.10 ± 0.30
P-value 0.913 0.162   0.795
e’
 No-AISC 6.92 ± 1.98 7.04 ± 2.42 0.599 0.14 ± 1.65
 AISC 7.85 ± 2.02 6.52 ± 2.08 0.001 -1.33 ± 0.34
P-value 0.067 0.365   0.001
TG
 No-AISC 1.25 (0.91, 1.55) 1.38 (0.98, 2.00) 0.004 0.22 (-0.08, 0.69)
 AISC 1.54 (1.27, 1.92) 2.01 (1.53, 3.15) 0.081 0.28 (-0.23, 1.23)
P-value 0.009 0.003   0.814
  1. Values are expressed as mean ± standard deviation or median (Q1-Q3). Bold values indicate statistical significance
  2. a Difference value of variables measured after 3 cycles of (R)-CHOP and at baseline
  3. AISC Anthracycline-induced subclinical cardiotoxicity, ApoA1 Apolipoprotein A1, DLBCL Diffuse large-B cell lymphoma, HDL-C High-density lipoprotein cholesterol, TG Total triglyceride